Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Duvelisib - Secura Bio

Next Previous
Search
Drug Profile

Duvelisib - Secura Bio

Alternative Names: ABBV-954; COPIKTRA; INK-1197; IPI-145; VS-0145; YHI-1702

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intellikine
  • Developer AbbVie; CSPC Pharmaceutical Group; Dana-Farber Cancer Institute; Infinity Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Secura Bio; Verastem Oncology; Yakult Honsha
  • Class Anti-inflammatories; Antiasthmatics; Antineoplastics; Antirheumatics; Isoquinolines; Purines; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - T-cell lymphoma; Chronic lymphocytic leukaemia; Peripheral T-cell lymphoma; Follicular lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia
  • Registered Follicular lymphoma
  • Phase III Non-Hodgkin's lymphoma
  • Phase II COVID 2019 infections; Haematological malignancies; Peripheral T-cell lymphoma; Squamous cell cancer
  • Phase I/II Malignant melanoma
  • No development reported Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours; T-cell lymphoma
  • Discontinued Allergic asthma; Rheumatoid arthritis

Most Recent Events

  • 28 Mar 2025 No recent reports of development identified for phase-I development in Precursor-cell-lymphoblastic-leukaemia-lymphoma(Second-line therapy or greater) in USA (PO, Capsule)
  • 09 Dec 2024 Updated efficacy and adverse event data from the phase II PRIMO trial in Peripheral T-cell lymphoma released by Secura Bio
  • 09 Dec 2024 Secura Bio plans a phase III TERZO trial in Peripheral T-cell lymphoma (Monotherapy; Second-line therapy or greater) in the EU and UK (PO) in the first half of 2025 (NCT06522737) (EudraCT2024-516605-23-00)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top